NASDAQ:TSVT 2seventy bio (TSVT) Stock Price, News & Analysis $4.95 0.00 (0.00%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$4.93 -0.02 (-0.30%) As of 03/14/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About 2seventy bio Stock (NASDAQ:TSVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 2seventy bio alerts:Sign Up Key Stats Today's Range$4.94▼$4.9650-Day Range$2.30▼$4.9552-Week Range$2.29▼$5.99Volume2.04 million shsAverage Volume641,192 shsMarket Capitalization$255.36 millionP/E RatioN/ADividend YieldN/APrice Target$6.67Consensus RatingHold Company Overview2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads 2seventy bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreTSVT MarketRank™: 2seventy bio scored higher than 62% of companies evaluated by MarketBeat, and ranked 411th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus Rating2seventy bio has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 2 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst Coverage2seventy bio has only been the subject of 4 research reports in the past 90 days.Read more about 2seventy bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 2seventy bio are expected to grow in the coming year, from ($1.46) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 2seventy bio is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 2seventy bio is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio2seventy bio has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 2seventy bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.18% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in 2seventy bio has recently decreased by 6.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield2seventy bio does not currently pay a dividend.Dividend Growth2seventy bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.18% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in 2seventy bio has recently decreased by 6.61%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment0.26 News Sentiment2seventy bio has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for 2seventy bio this week, compared to 2 articles on an average week.Search Interest2 people have searched for TSVT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 2seventy bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,350,607.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of 2seventy bio is held by insiders.Percentage Held by Institutions93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 2seventy bio's insider trading history. Receive TSVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TSVT Stock News Headlines2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in StockMarch 14 at 6:39 AM | insidertrades.com2seventy bio (NASDAQ:TSVT) Price Target Lowered to $5.00 at Morgan StanleyMarch 15 at 3:37 AM | americanbankingnews.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.March 15, 2025 | Brownstone Research (Ad)2seventy Bio price target lowered to $5 from $6 at Morgan StanleyMarch 14 at 12:21 PM | markets.businessinsider.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTMarch 14 at 11:24 AM | businesswire.comBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMarch 13 at 4:17 PM | msn.comLeerink Partners Reiterates Market Perform Rating for 2seventy bio (NASDAQ:TSVT)March 13 at 2:41 AM | americanbankingnews.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVTMarch 12 at 1:47 PM | prnewswire.comSee More Headlines TSVT Stock Analysis - Frequently Asked Questions How have TSVT shares performed this year? 2seventy bio's stock was trading at $2.94 on January 1st, 2025. Since then, TSVT stock has increased by 68.4% and is now trading at $4.95. View the best growth stocks for 2025 here. How were 2seventy bio's earnings last quarter? 2seventy bio, Inc. (NASDAQ:TSVT) posted its quarterly earnings data on Tuesday, March, 5th. The company reported ($1.11) EPS for the quarter, beating analysts' consensus estimates of ($1.22) by $0.11. The business had revenue of $10.68 million for the quarter, compared to analyst estimates of $13.91 million. 2seventy bio had a negative net margin of 207.25% and a negative trailing twelve-month return on equity of 53.65%. Who are 2seventy bio's major shareholders? Top institutional investors of 2seventy bio include Newtyn Management LLC (4.91%), Bank of America Corp DE (4.88%), Regeneron Pharmaceuticals Inc. (2.43%) and Eversept Partners LP (1.95%). Insiders that own company stock include Kynam Capital Management, Lp, Casdin Capital, Llc, Nick Leschly, Victoria Eatwell, Philip D Gregory, William D Baird III, Jessica Snow, Nicola Heffron, Marcela V Maus and Global Healthcare Master Kynam. View institutional ownership trends. How do I buy shares of 2seventy bio? Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 2seventy bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings3/05/2024Today3/15/2025Next Earnings (Estimated)3/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSVT CIK1860782 Webwww.2seventybio.com Phone339-499-9300FaxN/AEmployees440Year FoundedN/APrice Target and Rating Average Stock Price Target$6.67 High Stock Price Target$12.00 Low Stock Price Target$2.00 Potential Upside/Downside+34.7%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-217,570,000.00 Net Margins-207.25% Pretax Margin-207.25% Return on Equity-53.65% Return on Assets-23.67% Debt Debt-to-Equity RatioN/A Current Ratio4.95 Quick Ratio4.95 Sales & Book Value Annual Sales$45.62 million Price / Sales5.60 Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book0.98Miscellaneous Outstanding Shares51,588,000Free Float47,874,000Market Cap$255.36 million OptionableOptionable Beta1.73 7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:TSVT) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.